Clincosm LogoSign in Get a demo

her2

Showing 1 - 8 of 8
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting
  • Non-Muscle Invasive Bladder Cancer
  • HER2
  • (no location specified)
Jul 16, 2023

HER2, Colorectal Cancer Trial (Disitamab Vedotin Combined With Fruquintinib)

Not yet recruiting
  • HER2
  • Colorectal Cancer
  • Disitamab Vedotin Combined With Fruquintinib
  • (no location specified)
Dec 21, 2022

HER2-overexpressed Advanced Solid Tumors After Progression of

Not yet recruiting
  • HER2
  • +3 more
  • Disitamab Vedotin
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Dec 14, 2022

CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems

Completed
  • Breast Cancer
  • +7 more
    • Beijing, Beijing, China
    • +11 more
    Sep 25, 2020

    vs Upfront Surgery in HER2 Positive Early Breast Cancer

    Completed
    • Breast Cancer
    • +2 more
    • Preoperative systemic treatment
    • (no location specified)
    Sep 23, 2020

    Breast Cancer, Metastatic Breast Cancer, MBC Trial in United States (Lucitanib)

    Terminated
    Has Results
    • Breast Cancer
    • +7 more
    • Sedona, Arizona
    • +32 more
    Jun 20, 2020

    Targeted Therapy, HER2, Biliary Tract Cancer Trial in Beijing (chemo in combination with trastuzumab for arm1, chemo in

    Unknown status
    • Targeted Therapy
    • +4 more
    • chemotherapy in combination with trastuzumab for arm1
    • +3 more
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jul 17, 2019

    Advanced Gastric Cancer, HER2 Trial in Seoul (PF00299804)

    Completed
    • Advanced Gastric Cancer
    • HER2
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Nov 17, 2015